| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3063857 | Journal of Neuroimmunology | 2016 | 5 Pages |
•Serum IL-27 & IL-35 levels are decreased in neuromyelitis optica spectrum disorders.•IL-27 & IL-35 levels are inversely correlated with disease severity.•IL-27 & IL-35 are potential biomarkers of NMOSD severity.•IL-27 & IL-35 are potential cytokine therapeutics for NMOSD.
The interleukin 12 (IL-12) family plays important roles in autoimmune diseases. To explore the roles of the IL-12 family members IL-27 and IL-35 in the pathogenesis of neuromyelitis optica spectrum disorders (NMOSD), we determined their serum and cerebral spinal fluid levels and assessed potential correlations with clinical characteristics. Serum IL-27 levels were negatively correlated with disease severity and spinal cord lesion length, while serum IL-35 levels were negatively correlated with disease severity and annual relapse rate. Thus, IL-27 and IL-35 may be important biomarkers of NMOSD severity and these molecules might represent potential therapeutic cytokines for treating NMOSD.
Graphical abstractFigure optionsDownload full-size imageDownload high-quality image (93 K)Download as PowerPoint slide
